# Aryl-Cyclohexanone as a Potential CB2 Agonist: In Vitro and In Silico Evidence in Inflammatory Modulation. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/aryl-cyclohexanone-as-a-potential-cb2-agonist-in-vitro-and-in-silico-eviden/ > **Published:** 2026-04-28T22:02:09-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T16:05:14-04:00 > **Clinical Summary:** Inflammation is an evolutionarily conserved adaptive process essential for host defense against harmful stimuli, aimed at restoring homeostasis. However, exa... --- CED Clinical Relevance  #56Monitored Relevance  Early-stage or contextual signal requiring further evidence before action. 🔬 Evidence Watch  |  CED Clinic Journal Immunopharmacology and immunotoxicology Study Type [Clinical Study](https://cedclinic.com/cannabis-hyperemesis-syndrome-psychiatric-risk/) Population Human participants Why This Matters This item covers developments relevant to [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) and [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/). Clinicians monitoring evidence in this area should review the source material. Clinical Summary Inflammation is an evolutionarily conserved adaptive process essential for host defense against harmful stimuli, aimed at restoring homeostasis. However, exacerbated or dysregulated responses are associated with the progression of several autoimmune and chronic [inflammatory diseases](https://cedclinic.com/citral-cannabinoid-receptor-2-activation-pain-relief/), representing a significant clinical challenge. The [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) has been described as an important immunomodulatory pathway in which synthetic cannabinoids exert immunosuppressive effects, providing novel therapeutic targets. Aryl-Cyclohexanone (AD) has previously demonstrated anti-inflammatory properties in both Herein we aimed to investigate its immunomodulatory profile In J774 macrophages, AD treatment preserved cell viability, reduced nitric oxide metabolites production, normalized apoptotic events, and enhanced phagocytosis. Additionally, decreased Toll-like receptor 4 and increased mannose receptor (CD206) expressions were observed, along with a significant reduction in pro-inflammatory cyt Dr. Caplan’s Take “This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.” Clinical Perspective 🧠 Clinicians should review this item in the context of their current practice and patient population. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Aryl-Cyclohexanone%20as%20a%20Potential%20CB2%20Agonist%3A%20In%20Vitro%20and%20In%20Silico%20Evidence%20in%20Inflammatory%20Modul...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Faryl-cyclohexanone-as-a-potential-cb2-agonist-in-vitro-and-in-silico-eviden%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Faryl-cyclohexanone-as-a-potential-cb2-agonist-in-vitro-and-in-silico-eviden%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Aryl-Cyclohexanone%20as%20a%20Potential%20CB2%20Agonist%3A%20In%20Vitro%20and%20In%20Silico%20Evidence%20in%20Inflammatory%20Modul...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Faryl-cyclohexanone-as-a-potential-cb2-agonist-in-vitro-and-in-silico-eviden%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41937628/](https://pubmed.ncbi.nlm.nih.gov/41937628/) Table of Contents - [FAQ](#FAQ)[Why is dysregulated inflammation an important target for new treatments?](#Why_is_dysregulated_inflammation_an_important_target_for_new_treatments) - [How is the endocannabinoid system connected to inflammation?](#How_is_the_endocannabinoid_system_connected_to_inflammation) - [What is aryl-cyclohexanone, and why was it studied?](#What_is_aryl-cyclohexanone_and_why_was_it_studied) - [What effects did aryl-cyclohexanone have on macrophages?](#What_effects_did_aryl-cyclohexanone_have_on_macrophages) - [Related](#Related) ## FAQ ### Why is dysregulated inflammation an important target for new treatments? Inflammation is an evolutionarily conserved process essential for host defense against harmful stimuli and for restoring homeostasis. However, exacerbated or dysregulated inflammatory responses are associated with the progression of several autoimmune and chronic [inflammatory diseases](https://cedclinic.com/citral-cannabinoid-receptor-2-activation-pain-relief/), which represents a significant clinical challenge. ### How is the endocannabinoid system connected to inflammation? The [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) has been described as an important immunomodulatory pathway, meaning it helps regulate immune responses. Within this pathway, synthetic cannabinoids exert immunosuppressive effects, which is why it is seen as a source of novel therapeutic targets for inflammatory conditions. ### What is aryl-cyclohexanone, and why was it studied? Aryl-cyclohexanone, abbreviated AD, is a compound that had previously demonstrated anti-inflammatory properties. Building on that earlier work, the researchers aimed to investigate its immunomodulatory profile by testing its effects on J774 macrophages. ### What effects did aryl-cyclohexanone have on macrophages? In J774 macrophages, treatment with aryl-cyclohexanone preserved cell viability, reduced production of nitric oxide metabolites, normalized apoptotic events and enhanced phagocytosis. The researchers also observed decreased Toll-like receptor 4 expression and increased mannose receptor (CD206) expression. The summary does not describe any testing in patients. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).